Orion Oyj (OTCMKTS:ORINY – Get Free Report) hit a new 52-week low on Wednesday . The stock traded as low as $19.00 and last traded at $19.00, with a volume of 0 shares changing hands. The stock had previously closed at $19.00.
Analysts Set New Price Targets
Separately, Jefferies Financial Group raised shares of Orion Oyj from an “underperform” rating to a “hold” rating in a report on Tuesday.
Orion Oyj Price Performance
Orion Oyj (OTCMKTS:ORINY – Get Free Report) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.24 EPS for the quarter. The company had revenue of $327.71 million during the quarter. Orion Oyj had a return on equity of 21.29% and a net margin of 14.96%.
About Orion Oyj
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Precedex for intensive care sedative, as well as Fareston for breast cancer.
- Five stocks we like better than Orion Oyj
- What Does Downgrade Mean in Investing?
- Williams-Sonoma is a steal for buy-and-hold investors
- Investing In Preferred Stock vs. Common Stock
- A closer look at Warren Buffett’s latest surprise purchase
- Investing in Travel Stocks Benefits
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for Orion Oyj Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orion Oyj and related companies with MarketBeat.com's FREE daily email newsletter.